Floatz logo

Therapeutic Asset Ratings

766 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
[177lu]lu-dpi-4452
Nonpapillary Renal Cell Carcinoma
ITM Oncologics GmbHP1/2CCC (48)
[177lu]lu-dpi-4452
Head And Neck Cancer
ITM Oncologics GmbHP1/2CCC (48)
[177lu]lu-dpi-4452
Kidney Neoplasm
ITM Oncologics GmbHP1/2CCC (48)
[177lu]lu-dpi-4452
Infiltrating Bladder Urothelial Carcinoma
ITM Oncologics GmbHP1/2CCC (48)
[177lu]lu-sn201
Cancer
Spago Nanomedical ABP1/2CCC (48)
[18f]f-resca-rt4
Ovarian Cancer
RenJi HospitalP2/3CCC (48)
[18f]f-resca-rt4
Prostate Cancer
RenJi HospitalP2/3CCC (48)
[18f]f-resca-rt4
Neoplasm
RenJi HospitalP2/3CCC (48)
[212pb]pb-mp0712
Gastroenteropancreatic NEC (GEP NEC)
Molecular Partners AGP1/2CCC (48)
[212pb]pb-mp0712
Large Cell Neuroendocrine Carcinoma
Molecular Partners AGP1/2CCC (48)
[212pb]pb-mp0712
Pulmonary Large Cell Neuroendocrine Carcinoma
Molecular Partners AGP1/2CCC (48)
[212pb]pb-mp0712
Urinary Bladder Small Cell Neuroendocrine Carcinoma
Molecular Partners AGP1/2CCC (48)
[212pb]pb-mp0712
Other DLL3 Expressing epNEC
Molecular Partners AGP1/2CCC (48)
[212pb]vmt01
Cutaneous Melanoma
Perspective TherapeuticsP1/2CCC (48)
[225Ac]-FPI-1966
FGFR3
Fusion Pharmaceuticals Inc.P1/2CCC (48)
[225Ac]-FPI-1966
FGFR3 Overexpression
Fusion Pharmaceuticals Inc.P1/2CCC (48)
[225Ac]-FPI-1966
FGFR3 Protein Overexpression
Fusion Pharmaceuticals Inc.P1/2CCC (48)
[225Ac]-FPI-1966
FGFR3 Receptor
Fusion Pharmaceuticals Inc.P1/2CCC (48)
[225Ac]-FPI-1966
Susceptible FGFR3 Genetic Alterations
Fusion Pharmaceuticals Inc.P1/2CCC (48)
64cu-grip b
Carcinoma Of Urethra
Rahul AggarwalP1/2CCC (48)
64cu-lnth-1363s
Sarcoma
Lantheus Medical ImagingP1/2CCC (48)
[68ga]ga-nota-rt4
Ovarian Cancer
RenJi HospitalP2/3CCC (48)
[68ga]ga-nota-rt4
Prostate Cancer
RenJi HospitalP2/3CCC (48)
[68ga]ga-nota-rt4
Neoplasm
RenJi HospitalP2/3CCC (48)
[68ga]ga-nota-t4
Ovarian Cancer
RenJi HospitalP2/3CCC (48)
Showing 151 to 175 of 766 assets
PreviousPage 7 of 31Next